Market Overview

UPDATE: Piper Jaffray Raises PT to $48 on Medtronic on Solid Quarter, Conservative Guidance

Related MDT
Edwards Lifesciences Raised to Buy - Analyst Blog
ARCA biopharma Announces Screening of First Patient in Phase 2B/3 Clinical Trial Evaluating Gencaro in Atrial Fibrillation

Piper Jaffray reiterated its Overweight rating on Medtronic (NYSE: MDT) and raised its price target from $45 to $48.

Piper Jaffray noted, "While FY13 revenue guidance increased from 2%-4% to 3%-4%, guidance assumes a deceleration in sequential 2H13 growth (vs. 5% cc growth in F1H13). We view this as conservatism on the part of MDT's CEO, and believe this is appropriate given macro headwinds and product specific challenges. GMs were softer than expected, despite strong revenues, perpetuating the discussion on the leverage sustainability, especially given MDT's focus on EM growth. However, we note that the lower end of guidance did come up, and appreciate the renewed focus on meeting expectations. Overall, we view the results as positive."

Medtronic closed at $41.81 on Tuesday.

Posted-In: Piper JaffrayAnalyst Color Price Target Intraday Update Analyst Ratings

 

Most Popular

Related Articles (MDT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free